Latham & Watkins Advises CG Oncology in US$120 Million Series E Financing Round

CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, has announced the close of an oversubscribed US$120 million Series E financing round, co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital. The company has secured a total of over $200 million in funding to date. In connection with the financing, Brian Liu, M.D., Principal from Longitude Capital, will join the company’s board of directors.

Latham & Watkins LLP represented CG Oncology in the transaction with a corporate deal team led by San Diego partner Cheston Larson with associates Christian Hollweg, Alex Stuart-Lovell, and Bay Area associate Chris Pham. Additional advice on benefits and compensation matters was provided by San Diego partner Holly Bauer with Orange County associate Sara Schlau.